Abstract:Evidence has emerged that some healthy individuals with a history of exposure to Mycobacterium tuberculosis (Mtb) can develop protective antibody responses. However, it is not known whether patients with active tuberculosis elicit protective antibodies, and if they do, which bacterial antigens are targeted. To investigate the B cell responses during active infection, we generated a panel of monoclonal antibodies isolated from memory B cells of one patient. The antibodies, members of four distinct B cell clones, were directed against the Mtb phosphate transporter subunit PstS1. Antibodies p4–36 and p4–163 from two different B cell clones showed protective efficacy against Mtb and Mycobacterium bovis- BCG in an ex vivo human whole blood growth inhibition assay. Germline versions of p4–36 and p4–163 could no longer bind Mtb, implying that affinity maturation was vital for their activity. Crystal structures of p4–36 and a closely related clonal variant of p4–163, p4–170, complexed to PstS1 were determined at a resolution of 2.1Å and 2.4Å and revealed that the two antibodies recognize two distinctive epitopes on PstS1. As a proof of principle, p4–36 and p4–163 were used in a passive vaccination setting in aerosol Mtb-infected Balb/c mice, where both antibodies reduced bacterial lung burden by 50% after a single injection prior to Mtb infection. Our study shows that inhibitory B cell responses arise during active tuberculosis and identifies PstS1 as a target for elicitation of anti-Mtb antibodies. ### Competing Interest Statement The authors have declared no competing interest. ### Clinical Trial For human Tuberculosis patients: protocols number 33.18. and 0058, for healthy human donors: 2014-2-25 ### Funding Statement This study was funded by Israeli Science Foundation grant 1422/18 to N. T. Freund and Israeli Innovation Authority grant 65029 to N. T. Freund, as well as a National Natural Science Foundation of China grant (81661128044) to B. Javid, who is a Welcome Trust Investigator ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes all data associated with a paper is available, and can be accessed

Author Correction: an Anti-Lpqh Human Monoclonal Antibody from an Asymptomatic Individual Mediates Protection Against Mycobacterium Tuberculosis

Airway Macrophages Mediate Mucosal Vaccine-Induced Trained Innate Immunity against Mycobacterium tuberculosis in Early Stages of Infection.

Human antibodies targeting a Mycobacterium transporter protein mediate protection against tuberculosis.

Induction of an Immune-Protective T-Cell Repertoire with Diverse Genetic Coverage by a Novel Viral-Vectored Tuberculosis Vaccine in Humans

Human Antibodies Targeting a Transporter Mediate Protection Against Tuberculosis

Features and protective efficacy of human mAbs targeting Mycobacterium tuberculosis arabinomannan

Antibodies as key mediators of protection against Mycobacterium tuberculosis

Antibody-Fab and -Fc features promote Mycobacterium tuberculosis restriction.

Antigen-specific B cells direct T follicular-like helper cells into lymphoid follicles to mediate Mycobacterium tuberculosis control

Mycobacterial Lipoprotein Z Triggers Efficient Innate and Adaptive Immunity for Protection Against Mycobacterium Tuberculosis Infection

Mucosal Therapy of Multi-Drug Resistant Tuberculosis With IgA and Interferon-γ

Antigen specificity shapes antibody functions in tuberculosis.

Fc-engineered antibodies promote neutrophil-dependent control of Mycobacterium tuberculosis

Humoral correlate of vaccine-mediated protection from tuberculosis identified in humans and non-human primates

Correction: Performance of novel antibodies for lipoarabinomannan to develop diagnostic tests for Mycobacterium tuberculosis

T cell receptor repertoires associated with control and disease progression following Mycobacterium tuberculosis infection

Antibodies and tuberculosis: finally coming of age?

Author Correction: Specific CD4 + T cell phenotypes associate with bacterial control in people who 'resist' infection with Mycobacterium tuberculosis

Distinctive antibody responses to Mycobacterium tuberculosis in pulmonary and brain infection

Host and pathogen genetic diversity shape vaccine-mediated protection to Mycobacterium tuberculosis

The role of lymphocyte subsets in preventing tuberculosis following intravenous vaccination with BCG